Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Oncology Letters
|
March 15, 2019
Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer
Loredana Vesci, Valeria Carollo, Antonio Rosi, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
July 14, 2015
Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm
Claudio Albertoni, Barbara Leoni, Antonio Rosi, et al.
Oncotarget
|
February 11, 2017
AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies
Ferdinando Maria Milazzo, Anna Maria Anastasi, Caterina Chiapparino, et al.
The Journal of Biological Chemistry
|
January 27, 2010
Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties
Antonio Verdoliva, Piero Bellofiore, Vincenzo Rivieccio, et al.
Plos One
|
June 25, 2011
Chemical linkage to injected tissues is a distinctive property of oxidized avidin
Rita De Santis, Anna Maria Anastasi, Angela Pelliccia, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
April 29, 2010
AvidinOX for highly efficient tissue-pretargeted radionuclide therapy
Rita De Santis, Barbara Leoni, Antonio Rosi, et al.
Bioorganic & Medicinal Chemistry
|
June 19, 2019
Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors
Giuseppe Giannini, Ferdinando Maria Milazzo, Gianfranco Battistuzzi, et al.
Journal of Biomedicine & Biotechnology
|
February 5, 2010
OXavidin for tissue targeting biotinylated therapeutics
Rita De Santis, Claudio Albertoni, Antonio Rosi, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
September 25, 2010
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans
Fiorella Petronzelli, Angela Pelliccia, Anna Maria Anastasi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Improved tumor targeting by combined use of two antitenascin antibodies
Fiorella Petronzelli, Angela Pelliccia, Anna Maria Anastasi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Oncology Letters
|
March 15, 2019
Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer
Loredana Vesci, Valeria Carollo, Antonio Rosi, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
July 14, 2015
Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm
Claudio Albertoni, Barbara Leoni, Antonio Rosi, et al.
Oncotarget
|
February 11, 2017
AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies
Ferdinando Maria Milazzo, Anna Maria Anastasi, Caterina Chiapparino, et al.
The Journal of Biological Chemistry
|
January 27, 2010
Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties
Antonio Verdoliva, Piero Bellofiore, Vincenzo Rivieccio, et al.
Plos One
|
June 25, 2011
Chemical linkage to injected tissues is a distinctive property of oxidized avidin
Rita De Santis, Anna Maria Anastasi, Angela Pelliccia, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
April 29, 2010
AvidinOX for highly efficient tissue-pretargeted radionuclide therapy
Rita De Santis, Barbara Leoni, Antonio Rosi, et al.
Bioorganic & Medicinal Chemistry
|
June 19, 2019
Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors
Giuseppe Giannini, Ferdinando Maria Milazzo, Gianfranco Battistuzzi, et al.
Journal of Biomedicine & Biotechnology
|
February 5, 2010
OXavidin for tissue targeting biotinylated therapeutics
Rita De Santis, Claudio Albertoni, Antonio Rosi, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
September 25, 2010
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans
Fiorella Petronzelli, Angela Pelliccia, Anna Maria Anastasi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Improved tumor targeting by combined use of two antitenascin antibodies
Fiorella Petronzelli, Angela Pelliccia, Anna Maria Anastasi, et al.
Page
of 2